• Low-Affinity Blockade of N-Type Ca Channels by v-Agatoxin-IV

  2026-06-08

  This article examines the landmark study on the pharmacological properties of v-agatoxin-IVA and its selective and low-affinity blockade of neuronal N-type calcium channels. The findings clarify the molecular identity and functional diversity of high-threshold calcium channels in mammalian neurons, informing future neuroprotection and channel-selective research strategies.

• Deferasirox (Exjade): Pharmacokinetics and Iron Overload Res

  2026-06-08

  Galanello and colleagues provide a rigorous review of Deferasirox (Exjade) focusing on its pharmacokinetics, clinical efficacy, and safety for managing chronic iron overload in transfusion-dependent anemias. Their analysis establishes Deferasirox as a highly practical oral iron chelator with manageable risk, while highlighting ongoing challenges in optimizing iron burden monitoring and patient response.

• ROS-Degradable Lipid Nanoparticles for Tumor-Selective mRNA

  2026-06-07

  This study introduces a library of biodegradable lipid nanoparticles that leverage high intracellular ROS levels in cancer cells for selective mRNA delivery and gene expression. By screening and optimizing lipid structures, the authors achieved enhanced targeting of tumor cells, culminating in effective blockade of mutant RAS signaling and suppression of tumor growth.

• N1-Methyl-Pseudouridine-5'-Triphosphate in Advanced RNA Work

  2026-06-06

  Harness the unique benefits of N1-Methyl-Pseudouridine-5'-Triphosphate to boost RNA stability and translational efficiency in in vitro transcription and mRNA therapeutics. This guide delivers actionable workflows, troubleshooting insights, and lessons from cutting-edge retrotransposon research for reliable, high-yield RNA synthesis.

• BI 2536: Unraveling PLK1 Inhibition for Mitotic Checkpoint C

  2026-06-05

  Discover how BI 2536, a potent PLK1 inhibitor, advances the mechanistic understanding of mitotic checkpoint disassembly and apoptosis induction in cancer research. This article uniquely bridges cutting-edge reference data with practical assay guidance.

• MLKL Polymerization Drives Lysosomal Permeabilization in Nec

  2026-06-05

  Liu et al. reveal that MLKL polymerization at the lysosomal membrane is a direct trigger of lysosomal membrane permeabilization (LMP) during necroptosis, causing cytosolic release of active cathepsins—especially cathepsin B—which drive cell death. The study delineates a mechanistic link between necroptotic signaling and lysosomal rupture, providing a refined framework for targeting regulated cell death pathways in disease.

• Deferasirox (Exjade): Innovations in Iron Overload Managemen

  2026-06-04

  This review examines the pivotal findings of the FORMULARY REVIEW Deferasirox paper, focusing on the development and clinical validation of oral Deferasirox (Exjade) as a tridentate iron chelator for transfusional iron overload. The study demonstrates the compound’s efficacy and tolerability in chronic anemia contexts, marking a significant advance over traditional parenteral chelation strategies.

• TCF25 Modulates Lysosomal Cell Death Under Glucose Starvatio

  2026-06-04

  Ren et al. identify TCF25 as a nutrient sensor that enhances lysosomal acidification and drives cell fate decisions under glucose deprivation. These findings reveal new mechanistic connections between metabolic adaptation, autophagy, and lysosome-dependent cell death, highlighting TCF25 as a potential therapeutic target in metabolic and ischemic disorders.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-06-03

  Wang et al. uncover the METTL16-SENP3-LTF signaling axis as a key mechanism conferring ferroptosis resistance and promoting tumorigenesis in hepatocellular carcinoma (HCC). Their integrated molecular and in vivo study highlights the axis as a promising target for sensitizing HCC cells to ferroptosis, with implications for new cancer treatment strategies using iron chelation.

• Resibufogenin Inhibits NLRP3 to Reduce Atherosclerosis in Mi

  2026-06-03

  This study demonstrates that resibufogenin (RBG) directly blocks NLRP3 inflammasome assembly, leading to reduced inflammation and atherosclerotic plaque formation in ApoE-/- mice. The findings offer mechanistic insight into RBG as a potential therapeutic for cardiovascular disease and highlight advanced immunodetection tools relevant to translational research.

• Gepotidacin: Mechanistic Insight & Strategy for Translationa

  2026-06-02

  This thought-leadership article unpacks Gepotidacin’s (GSK2140944) distinctive mechanism as a triazaacenaphthylene bacterial type II topoisomerase inhibitor, guiding translational researchers through its experimental utility, clinical promise, and the strategic imperatives for combating antibiotic resistance. Drawing on clinical studies and advanced laboratory applications, we highlight APExBIO’s Gepotidacin as a cornerstone for next-generation antibacterial research, moving beyond conventional product narratives.

• Cy5 TSA Fluorescence System Kit: Precision Mapping in Neural

  2026-06-02

  Explore how the Cy5 TSA Fluorescence System Kit elevates signal amplification for immunohistochemistry and spatial transcriptomic studies. This article reveals expert protocol parameters and practical insights for resolving cellular diversity in neurobiology.

• YTHDF2 Inhibition Enhances m6A-Mediated Memory via Protein S

  2026-06-01

  This study reveals that forebrain-specific knockout of YTHDF2, a key m6A reader protein, enhances hippocampus-dependent learning and memory by reducing m6A-modified mRNA degradation and boosting synaptic protein synthesis. These findings clarify the regulatory role of YTHDF2 in neural plasticity, offering new directions for neuroepigenetic research and memory modulation.

• Levofloxacin: Advanced Mechanisms and Experimental Innovatio

  2026-06-01

  Discover the multifaceted research potential of Levofloxacin, a synthetic fluoroquinolone antibiotic. This in-depth article unveils novel assay methodologies, mechanistic insights, and practical guidance for leveraging Levofloxacin in antibacterial and bone metabolism studies.

• E. coli Uracil-DNA Glycosylase (UDG): Technical Use Guide

  2026-05-31

  E. coli Uracil-DNA Glycosylase (UDG) is designed to remove uracil residues from DNA, helping laboratories prevent PCR product contamination and improve amplification fidelity. It is not suitable for RNA substrates, oligonucleotides under six bases, or any diagnostic or medical applications.

16398 records 1/1094 page Next 12345 下5页 Last page